ERGOTAMINE TARTRATE AND CAFFEINE: Pharmaceutical manufacturers, suppliers, and distributors

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Anda Repository	ERGOTAMINE TARTRATE AND CAFFEINE	caffeine; ergotamine tartrate	TABLET;ORAL	040590	ANDA	Cintex Services, LLC	24470-917-10	100 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (24470-917-10)	2016-11-23
Anda Repository	ERGOTAMINE TARTRATE AND CAFFEINE	caffeine; ergotamine tartrate	TABLET;ORAL	040590	ANDA	Cintex Services, LLC	24470-917-40	40 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (24470-917-40)	2016-11-23
Anda Repository	ERGOTAMINE TARTRATE AND CAFFEINE	caffeine; ergotamine tartrate	TABLET;ORAL	040590	ANDA	Trifluent Pharma, LLC	73352-917-40	40 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (73352-917-40)	2026-03-23
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: February 19, 2026

This report analyzes the supply landscape for ergotamine tartrate and caffeine, key active pharmaceutical ingredients (APIs) used in combination therapies, primarily for migraine and cluster headaches. The analysis focuses on global manufacturing capabilities, regulatory considerations, and potential supply chain vulnerabilities.

Who are the Primary Manufacturers of Ergotamine Tartrate API?

The manufacturing of ergotamine tartrate API is concentrated among a limited number of specialized pharmaceutical chemical producers. Historical reliance on fermentation processes, often utilizing Claviceps purpurea ergot fungi, dictates the production complexity and regulatory scrutiny. Key global suppliers include:

Basf SE: A major chemical company with a diverse pharmaceutical ingredient portfolio, Basf has been involved in the production of ergotamine derivatives. Their manufacturing capabilities are supported by robust quality control systems and adherence to Good Manufacturing Practices (GMP).
Sanofi S.A.: As a large, vertically integrated pharmaceutical company, Sanofi has historically produced or sourced ergotamine tartrate for its finished drug products. Their internal supply chain management ensures rigorous quality standards.
Boehringer Ingelheim GmbH: This German pharmaceutical company has a history of producing complex APIs, including alkaloids. Their expertise in fermentation and downstream processing positions them as a potential supplier or strategic partner.
Smaller, Specialized Chemical Manufacturers: Several niche chemical synthesis companies, particularly in Europe and India, also produce ergotamine tartrate. These entities often operate with a focus on specific alkaloid production. Their scale may be smaller, but they can offer flexibility for specialized orders.

The production process involves complex extraction and purification steps, making it less accessible to a broad range of manufacturers. Regulatory hurdles, including stringent impurity profiling and stability testing, further limit the number of qualified API producers.

What are the Key Manufacturers of Caffeine API?

Caffeine, a widely used stimulant and potentiator of ergotamine's vasoconstrictive effects, has a broader manufacturing base compared to ergotamine tartrate. Production primarily involves chemical synthesis, making it more accessible to a larger number of global API suppliers. Major manufacturers include:

BASF SE: Similar to ergotamine tartrate, BASF is a significant producer of synthetic caffeine API, adhering to international pharmaceutical standards.
Abbott Laboratories: While known for finished drug products, Abbott also has a presence in API manufacturing, including commonly used compounds like caffeine.
Cargill, Incorporated: Primarily known for food ingredients, Cargill also produces purified caffeine, often meeting USP (United States Pharmacopeia) and EP (European Pharmacopoeia) specifications for pharmaceutical use.
Numerous Chinese and Indian API Manufacturers: A substantial volume of synthetic caffeine API is produced by companies in China and India. These manufacturers often compete on price and volume, but rigorous supplier qualification by pharmaceutical companies is essential to ensure quality and compliance. Examples include:
- Zhejiang NHU Co., Ltd. (China)
- Anqiu Lu'an Pharmaceutical Co., Ltd. (China)
- Divi's Laboratories Limited (India)
- Laurus Labs Limited (India)

The synthesis of caffeine is a well-established chemical process, allowing for larger production volumes and a more competitive market landscape. However, the critical factor for pharmaceutical applications remains the purity profile and adherence to pharmacopoeial monographs.

What are the Regulatory Requirements for Ergotamine Tartrate and Caffeine API?

The regulatory landscape for both ergotamine tartrate and caffeine API is governed by stringent guidelines to ensure product safety, efficacy, and quality.

Ergotamine Tartrate Specifics:

Good Manufacturing Practices (GMP): Manufacturers must adhere to cGMP as defined by regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). This includes comprehensive quality management systems, validated manufacturing processes, and robust analytical testing.
Pharmacopoeial Standards: API must meet the specifications outlined in major pharmacopoeias, including USP, EP, and Japanese Pharmacopoeia (JP). These monographs detail identity, purity, assay, and impurity limits.
Impurity Profiling: Due to the complex nature of ergotamine synthesis and its origins, thorough impurity profiling is critical. This includes identifying and quantifying related substances, residual solvents, and potential genotoxic impurities. Regulatory agencies require extensive data on impurity formation and control strategies.
Drug Master Files (DMFs): API manufacturers typically submit DMFs to regulatory agencies. These confidential documents contain detailed information about the manufacturing process, facilities, controls, and stability of the API. Pharmaceutical companies then reference these DMFs in their drug product applications.
Controlled Substance Status: In some jurisdictions, ergotamine and its derivatives may be subject to controlled substance regulations due to their potential for misuse or diversion, although this is less common for standard ergotamine tartrate API for legitimate medical use.

Caffeine Specifics:

GMP Compliance: Similar to ergotamine tartrate, caffeine API manufacturers must comply with cGMP.
Pharmacopoeial Standards: Caffeine API must meet USP, EP, JP, and other relevant pharmacopoeial standards.
Purity and Impurities: While caffeine synthesis is more straightforward, stringent limits on heavy metals, residual solvents, and specific organic impurities are enforced.
DMFs: DMF submissions are standard practice for caffeine API manufacturers supplying to regulated markets.

The co-formulation of ergotamine tartrate and caffeine into finished dosage forms requires that both APIs meet these rigorous standards independently and also demonstrate compatibility and stability within the final drug product.

What are the Potential Supply Chain Risks for Ergotamine Tartrate?

The supply chain for ergotamine tartrate presents several inherent risks due to its specialized nature:

Limited Manufacturer Base: The small number of qualified ergotamine tartrate API manufacturers creates a concentration risk. Disruptions at a single site due to regulatory non-compliance, quality issues, natural disasters, or geopolitical instability can have significant impacts.
Complex Manufacturing Process: The reliance on fermentation and complex extraction techniques is resource-intensive and requires specialized expertise and equipment. Scaling up production or bringing new manufacturers online is a time-consuming and capital-intensive process.
Raw Material Sourcing: The sourcing of raw materials, including the ergot fungi or precursor chemicals, can be subject to agricultural yields, environmental conditions, and geopolitical factors affecting specific geographic regions where these are cultivated or produced.
Regulatory Scrutiny and Enforcement: Any deviation from stringent GMP or pharmacopoeial standards can lead to regulatory actions, including import alerts, product recalls, or manufacturing site shutdowns, causing immediate supply disruptions.
Geopolitical Factors: Concentration of manufacturing in specific regions can expose the supply chain to risks associated with trade disputes, export restrictions, or political instability.
Long Lead Times: The complex production cycle means that lead times for ergotamine tartrate API orders can be substantial, making it difficult to respond rapidly to unexpected demand surges.

These risks necessitate robust supplier qualification processes, dual-sourcing strategies where feasible, and proactive inventory management by pharmaceutical companies.

What are the Potential Supply Chain Risks for Caffeine API?

While caffeine API has a broader supply base, it is not without its own set of supply chain risks:

Price Volatility: The competitive nature of the synthetic caffeine market can lead to price fluctuations based on raw material costs, energy prices, and global demand.
Quality Consistency Across Manufacturers: With a large number of manufacturers, particularly in emerging markets, ensuring consistent quality and compliance with pharmacopoeial standards requires rigorous supplier audits and incoming quality control testing. A single batch failing to meet specifications can disrupt production.
Geographic Concentration of Production: Despite a broader base, a significant portion of global caffeine API production is concentrated in China and India. This concentration exposes the supply chain to risks related to trade policies, environmental regulations, and local manufacturing disruptions.
Logistics and Transportation: Global sourcing of caffeine API relies on efficient logistics. Shipping delays, customs issues, or disruptions in shipping routes can impact timely delivery.
Intellectual Property and Counterfeiting: While caffeine itself is a generic compound, variations in purity or the potential for substandard or counterfeit API entering the supply chain remain a concern requiring vigilance.

The primary risk for caffeine API, in the context of ergotamine tartrate and caffeine combination products, lies in ensuring the quality and reliability of supply to match the more constrained ergotamine tartrate supply chain.

How Do Ergotamine Tartrate and Caffeine Interact within the Drug Product?

Ergotamine tartrate and caffeine are combined in pharmaceutical formulations, most notably for the treatment of migraines. Their interaction is synergistic:

Ergotamine Tartrate: This alkaloid has vasoconstrictive properties, particularly on cranial blood vessels. It is believed to exert its therapeutic effect by constricting dilated intracranial arteries that are thought to contribute to migraine pain. It also has effects on serotonin receptors.
Caffeine: Caffeine acts as an adjunct to ergotamine tartrate. Its primary role in this combination is to enhance the absorption of ergotamine tartrate from the gastrointestinal tract, thereby increasing its bioavailability. Caffeine also possesses its own mild vasoconstrictive effects and can help alleviate migraine pain through central nervous system stimulation and by potentiating the analgesic effects of ergotamine.

The co-formulation necessitates careful consideration of API compatibility, dissolution profiles, and the stability of both APIs in the final dosage form (e.g., tablets, suppositories).

What are the Key Considerations for Pharmaceutical Companies Sourcing These APIs?

Pharmaceutical companies seeking to source ergotamine tartrate and caffeine API must adopt a strategic approach, prioritizing reliability, quality, and regulatory compliance.

Supplier Qualification: Implement a robust supplier qualification program. This includes on-site audits, review of quality management systems, assessment of regulatory compliance history, and verification of GMP certification. For ergotamine tartrate, this vetting process needs to be exceptionally thorough due to the limited supplier pool.
Dual Sourcing Strategy: For critical APIs like ergotamine tartrate, wherever technically and economically feasible, pursue dual sourcing from different qualified manufacturers. This mitigates the risk of single-supplier dependency. For caffeine, this is generally more achievable.
Supply Chain Transparency and Traceability: Demand full transparency regarding the origin of raw materials, manufacturing sites, and sub-contractors. Establish clear traceability mechanisms from API batch to finished drug product.
Contractual Agreements: Develop strong contractual agreements that clearly define quality specifications, delivery schedules, change control procedures, intellectual property protection, and business continuity plans. Include provisions for audits and the right to terminate contracts for non-compliance.
Inventory Management and Buffer Stocks: Maintain adequate buffer stocks of both APIs to cover unforeseen supply disruptions. This requires careful demand forecasting and understanding the lead times associated with each API.
Regulatory Intelligence: Continuously monitor regulatory changes and enforcement actions related to API manufacturing in key sourcing regions. Proactively engage with regulatory agencies and stay informed about evolving compliance expectations.
Risk Mitigation Planning: Develop comprehensive risk mitigation plans for potential supply chain disruptions, including identifying alternative transportation routes, contingency manufacturing plans, and communication protocols for stakeholders.
Long-Term Supplier Relationships: Cultivate long-term, collaborative relationships with key API suppliers. This fosters trust, facilitates open communication, and can lead to preferential treatment during periods of high demand or supply constraints.

By addressing these considerations, pharmaceutical companies can build more resilient and reliable supply chains for ergotamine tartrate and caffeine, ensuring consistent availability of critical medications.

Key Takeaways

Ergotamine tartrate API manufacturing is concentrated among a limited number of specialized producers, posing significant supply chain concentration risk.
Caffeine API production is more widespread, with a larger number of manufacturers, primarily in China and India, offering greater sourcing flexibility but requiring diligent quality assurance.
Both APIs are subject to stringent GMP and pharmacopoeial standards, with ergotamine tartrate facing enhanced scrutiny due to its complex production and impurity profile.
Supply chain risks for ergotamine tartrate include limited capacity, complex manufacturing, raw material sourcing variability, and regulatory enforcement.
Caffeine API risks involve price volatility, quality consistency across a broad supplier base, and geographic production concentration.
The synergistic interaction of ergotamine tartrate (vasoconstriction) and caffeine (enhanced absorption, potentiation) is central to their therapeutic use in migraine treatment.
Pharmaceutical companies must implement rigorous supplier qualification, dual sourcing where possible, supply chain transparency, robust contracts, and proactive risk management to secure reliable API supply.

Frequently Asked Questions

What are the primary geographical regions for ergotamine tartrate API production? Ergotamine tartrate API production is primarily concentrated in Europe, with specific manufacturers located in countries with established pharmaceutical chemical industries.
Are there synthetic routes for ergotamine tartrate that bypass fermentation? While research into fully synthetic routes exists, commercial-scale production of ergotamine tartrate typically relies on fermentation processes involving Claviceps purpurea or related fungi.
How does the regulatory status of caffeine API differ from ergotamine tartrate API? Caffeine API is a widely produced commodity with standard pharmaceutical quality controls. Ergotamine tartrate API faces more stringent regulatory scrutiny due to its alkaloid nature, complex manufacturing, and more significant potential for side effects and impurity concerns.
What is the typical shelf life of ergotamine tartrate and caffeine APIs? The shelf life of both APIs, when stored under recommended conditions, generally ranges from two to five years. Specific stability data is provided by each manufacturer and is detailed in their respective DMFs and Certificates of Analysis.
Can ergotamine tartrate and caffeine APIs be sourced from the same suppliers? While some large chemical conglomerates like BASF may produce both APIs, it is rare for a single manufacturer to specialize in both the complex fermentation-based production of ergotamine tartrate and the large-scale synthetic production of caffeine. Pharmaceutical companies typically source these APIs from distinct, qualified suppliers.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Current Good Manufacturing Practice (CGMP) Regulations. Retrieved from [FDA Website] (Specific URL would depend on the exact document referenced, e.g., https://www.fda.gov/drugs/pharmaceutical-quality-resources/current-good-manufacturing-practice-cgmp-regulations)

[2] European Medicines Agency. (n.d.). Good Manufacturing Practice (GMP). Retrieved from [EMA Website] (Specific URL would depend on the exact document referenced, e.g., https://www.ema.europa.eu/en/human-regulatory/research-and-development/good-laboratory-practice-compliance)

[3] United States Pharmacopeia. (n.d.). Ergotamine Tartrate Monograph. (Access requires subscription or purchase).

[4] European Pharmacopoeia. (n.d.). Ergotamine Tartrate Monograph. (Access requires subscription or purchase).

[5] United States Pharmacopeia. (n.d.). Caffeine Monograph. (Access requires subscription or purchase).

[6] European Pharmacopoeia. (n.d.). Caffeine Monograph. (Access requires subscription or purchase).

Suppliers and packagers for ERGOTAMINE TARTRATE AND CAFFEINE